SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Morrow J, Nelson L, Watts R, Isenberg D. Autoimmune rheumatic disease. Oxford (UK): Oxford University Press; 1999.
  • 2
    Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 33846.
  • 3
    Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus: long-term followup of an inception cohort. Arthritis Rheum 1995; 38: 14929.
  • 4
    Manzi S. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology (Oxford) 2000; 39: 3539.
  • 5
    MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 1525.
  • 6
    Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 5339.
  • 7
    Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 156674.
  • 8
    Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 12114.
  • 9
    Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 9235.
  • 10
    Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 7935.
  • 11
    Ames PRJ, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 1999; 38: 52934.
  • 12
    Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 1524.
  • 13
    Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 47380.
  • 14
    Senti M, Tomas M, Vila J, Marrugat J, Elosua R, Sala J, et al. Relationship of age related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase 1 gene: the REGICOR study. Atherosclerosis 2001; 156: 4439.
  • 15
    Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk G, Paragh G. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients: a new hypothesis of the beneficial action of fibrates? Diabetes Metab 2001; 27: 60410.
  • 16
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 17
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 18
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 19
    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 44758.
  • 20
    Harris EN, Hughes GR. Standardising the anti-cardiolipin antibody test. Lancet 1987; 1: 277.
  • 21
    McNally T, Purdy G, Mackie IJ, Machin SJ, Isenberg DA. The use of an anti-beta 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91: 4713.
  • 22
    Mackness MI, Durrington PN. Lipoprotein analysis: a practical approach. Oxford (UK): IRL Press; 1992.
  • 23
    Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982; 23: 120623.
  • 24
    Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 112638.
  • 25
    Hochberg MC, Petri M. The association of corticosteroid therapy with coronary heart disease in patients with systemic lupus erythematosus: a meta-analysis [abstract]. Arthritis Rheum 1991; 34 Suppl 5: R24.
  • 26
    Borba EF, Bonfa E, Vinagre CGC, Ramires JAF, Maranhao RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 103340.
  • 27
    Williamson R, Lee D, Hagaman J, Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A 1992; 89: 71348.
  • 28
    Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK III, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97: 23819.
  • 29
    Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 11526.
  • 30
    Schisterman EF, Faraggi D, Browne R, Freudenheim J, Dorn J, Muti P, et al. TBARS and cardiovascular disease in a population-based sample. J Cardiovasc Risk 2001; 8: 21925.
  • 31
    Ames PRJ, Alves J, Pap AF, Ramos P, Khamashta MA, Hughes GRV. Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? J Rheumatol 2000; 27: 11905.
  • 32
    Ames PR, Nourooz-Zadeh J, Tommasino C, Alves J, Brancaccio V, Anggard EE. Oxidative stress in primary antiphospholipid syndrome. Thromb Haemost 1998; 79: 4479.
  • 33
    Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L, Schwartz JE, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 2001; 87: 6636.
  • 34
    Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titer and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 20814.
  • 35
    Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 56973.
  • 36
    Vaarala O. Antibodies to oxidised LDL. Lupus 2000; 9: 2025.
  • 37
    Horkko S, Olee T, Mo L. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein I and oxidized low-density lipoprotein. Circulation 2001; 103: 9416.
  • 38
    Wu R, Svenungsson E, Gunnarsson I, Andersson B, Lundberg I, Schafer EL, et al. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus 1999; 8: 14250.
  • 39
    Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998; 7: 35560.
  • 40
    Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K, et al. Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 9905.
  • 41
    Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19: 221425.
  • 42
    Lambert M, Boullier A, Hachulla E, Fruchart JC, Teissier E, Hatron PY, et al. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 2000; 9: 299300.
  • 43
    Deguchi H, Fernandez JA, Hackeng TM, Banka CL, Griffin JH. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci U S A 2000; 97: 17438.
  • 44
    Nuttall SL, Heaton S, Piper MK, Martin U, Kendall MJ, Gordon C. Oxidative stress and small dense low density lipoproteins (LDL) in systemic lupus erythematosus [abstract]. Rheumatology 2001; 40 Suppl 1: 112 A.
  • 45
    Mackness B, Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 1999; 353: 4689.
  • 46
    Lin KY, Pan JP, Yang DL, Huang KT, Chang MS, Ding PY, et al. Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (beta2-glycoprotein I). Life Sci 2001; 69: 70719.